Oportuzumab monatox

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Oportuzumab monatox
Monoclonal antibody
TypeSingle-chain variable fragment
SourceHumanized
TargetEpCAM
Clinical data
Trade namesVicineum
ATC code
  • None
Identifiers
CAS Number
  • 945228-48-8 ☒N
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC3072H4723N877O952S12
Molar mass69558.48 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Oportuzumab monatox (proposed INN, trade name Vicineum) is an antineoplastic. Chemically, oportuzumab is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the drug's name).[1]

The drug was originally developed by Canadian-based Viventia Bio Inc. The company was acquired by Cambridge(MA)-based Eleven Biotherapeutics in 2016 which then changed its name to Sesen Bio.[2] In 2019 Sesen Bio reported updated, preliminary primary and secondary endpoint data from the company's Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicineum for the potential treatment of patients with high-risk, bacillus Calmette-Guérin(BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).[3] The Company applied for approval of Vicineum by the United States Food and Drug Administration und the European Medicines Agency.

References[edit]

Vol 24, No 18S (June 20 Supplement), 2006: 4580